FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2162079719> ?p ?o ?g. }

• W2162079719 endingPage "262" @default.
• W2162079719 startingPage "257" @default.
• W2162079719 abstract "The Patient Assistance Program, a type of expanded access program, was initiated for compassionate purposes to provide ipilimumab to patients with unresectable stage III or IV melanoma with failed previous treatment. The aim of this analysis is to evaluate efficacy, safety, and tolerability of ipilimumab therapy in daily clinical practice.We analyzed 50 patients (29 males, 21 females) aged 21 to 76 years (median: 49 years). An ipilimumab dose of 3 mg/kg was administered intravenously every 3 weeks for a total of 4 doses. Patients were assessed for response rate, progression-free survival and overall survival, and monitored for adverse events.The objective response (complete or partial response) rate was 12%. Median overall survival was 8 months and median progression-free survival was 3 months. In patients with ECOG-PS 0, the median overall survival was 16 months. Immune-related adverse events (irAEs) occurred in 48% of the patients, grade 3 or 4 irAEs were reported in 8% of the patients, and there were no toxic deaths.Ipilimumab demonstrated clinical benefit in previously treated advanced melanoma patients. Although clinical benefit is limited to a minority of the patients, there is a benefit in terms of overall survival in this group of patients." @default.
• W2162079719 created "2016-06-24" @default.
• W2162079719 creator A5001159949 @default.
• W2162079719 creator A5005706056 @default.
• W2162079719 creator A5007834158 @default.
• W2162079719 creator A5023541358 @default.
• W2162079719 creator A5025617578 @default.
• W2162079719 creator A5031394337 @default.
• W2162079719 creator A5054110229 @default.
• W2162079719 creator A5064766623 @default.
• W2162079719 creator A5073907665 @default.
• W2162079719 creator A5074975947 @default.
• W2162079719 date "2013-01-01" @default.
• W2162079719 modified "2023-10-02" @default.
• W2162079719 title "Efficacy and safety of ipilimumab therapy in patients with metastatic melanoma: a retrospective multicenter analysis" @default.
• W2162079719 cites W1529517822 @default.
• W2162079719 cites W1967084952 @default.
• W2162079719 cites W1977607846 @default.
• W2162079719 cites W1980664511 @default.
• W2162079719 cites W2020727013 @default.
• W2162079719 cites W2054535181 @default.
• W2162079719 cites W2069805376 @default.
• W2162079719 cites W2081521066 @default.
• W2162079719 cites W2094366129 @default.
• W2162079719 cites W2095826876 @default.
• W2162079719 cites W2097995306 @default.
• W2162079719 cites W2100158834 @default.
• W2162079719 cites W2102031533 @default.
• W2162079719 cites W2103220202 @default.
• W2162079719 cites W2112069616 @default.
• W2162079719 cites W2118503880 @default.
• W2162079719 cites W2118863192 @default.
• W2162079719 cites W2119198740 @default.
• W2162079719 cites W2123363005 @default.
• W2162079719 cites W2141756397 @default.
• W2162079719 cites W2145853100 @default.
• W2162079719 cites W2151507811 @default.
• W2162079719 cites W2164918836 @default.
• W2162079719 cites W2280151081 @default.
• W2162079719 cites W2587777872 @default.
• W2162079719 cites W67197765 @default.
• W2162079719 doi "https://doi.org/10.5114/wo.2013.35785" @default.
• W2162079719 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3934064" @default.
• W2162079719 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24596511" @default.
• W2162079719 hasPublicationYear "2013" @default.
• W2162079719 type Work @default.
• W2162079719 sameAs 2162079719 @default.
• W2162079719 citedByCount "12" @default.
• W2162079719 countsByYear W21620797192013 @default.
• W2162079719 countsByYear W21620797192015 @default.
• W2162079719 countsByYear W21620797192017 @default.
• W2162079719 countsByYear W21620797192019 @default.
• W2162079719 countsByYear W21620797192020 @default.
• W2162079719 countsByYear W21620797192021 @default.
• W2162079719 countsByYear W21620797192023 @default.
• W2162079719 crossrefType "journal-article" @default.
• W2162079719 hasAuthorship W2162079719A5001159949 @default.
• W2162079719 hasAuthorship W2162079719A5005706056 @default.
• W2162079719 hasAuthorship W2162079719A5007834158 @default.
• W2162079719 hasAuthorship W2162079719A5023541358 @default.
• W2162079719 hasAuthorship W2162079719A5025617578 @default.
• W2162079719 hasAuthorship W2162079719A5031394337 @default.
• W2162079719 hasAuthorship W2162079719A5054110229 @default.
• W2162079719 hasAuthorship W2162079719A5064766623 @default.
• W2162079719 hasAuthorship W2162079719A5073907665 @default.
• W2162079719 hasAuthorship W2162079719A5074975947 @default.
• W2162079719 hasBestOaLocation W21620797191 @default.
• W2162079719 hasConcept C121608353 @default.
• W2162079719 hasConcept C126322002 @default.
• W2162079719 hasConcept C141071460 @default.
• W2162079719 hasConcept C143998085 @default.
• W2162079719 hasConcept C167135981 @default.
• W2162079719 hasConcept C197934379 @default.
• W2162079719 hasConcept C2775832928 @default.
• W2162079719 hasConcept C2776283816 @default.
• W2162079719 hasConcept C2777658100 @default.
• W2162079719 hasConcept C2777701055 @default.
• W2162079719 hasConcept C2778375690 @default.
• W2162079719 hasConcept C2779984678 @default.
• W2162079719 hasConcept C2781433595 @default.
• W2162079719 hasConcept C31760486 @default.
• W2162079719 hasConcept C502942594 @default.
• W2162079719 hasConcept C535046627 @default.
• W2162079719 hasConcept C71924100 @default.
• W2162079719 hasConceptScore W2162079719C121608353 @default.
• W2162079719 hasConceptScore W2162079719C126322002 @default.
• W2162079719 hasConceptScore W2162079719C141071460 @default.
• W2162079719 hasConceptScore W2162079719C143998085 @default.
• W2162079719 hasConceptScore W2162079719C167135981 @default.
• W2162079719 hasConceptScore W2162079719C197934379 @default.
• W2162079719 hasConceptScore W2162079719C2775832928 @default.
• W2162079719 hasConceptScore W2162079719C2776283816 @default.
• W2162079719 hasConceptScore W2162079719C2777658100 @default.
• W2162079719 hasConceptScore W2162079719C2777701055 @default.
• W2162079719 hasConceptScore W2162079719C2778375690 @default.
• W2162079719 hasConceptScore W2162079719C2779984678 @default.
• W2162079719 hasConceptScore W2162079719C2781433595 @default.
• W2162079719 hasConceptScore W2162079719C31760486 @default.

• next